NINDS ADRD K99/R00 – Independent Clinical Trial Not Allowed – PAR-22-022
Due Dates for New Applications
February 12, June 12, October 12
Due Dates for Resubmission Applications
March 12, July 12, November 12
U.S. citizens or permanent residents; research doctorate holders; members of underrepresented groups
U.S. domestic institutions
This program is designed to facilitate a timely transition of postdoctoral researchers from diverse backgrounds conducting AD/ADRD research into independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees establish independent research programs in the AD/ADRD field.
Applicants are strongly encouraged to consult with NIH scientific/research staff as early as possible before the due date when planning an application. Early contact provides an opportunity for NIH scientific/research staff to provide guidance on program scope and appropriateness of the proposed research and training for potential funding in response to this FOA. Applications that do not fit the NINDS AD/ADRD mission focused research areas will be withdrawn.
Applications appropriate for this FOA may propose biomedical research across the spectrum of AD/ADRD, including AD, Lewy body dementia, vascular contributions to cognitive impairment and dementia, frontotemporal dementia, and mixed dementias, especially mixed with cerebrovascular disease or Lewy bodies. The pre-symptomatic, early symptomatic, and dementia stages of these diseases and syndromes can be addressed. Applications may include, but are not limited to, the following research areas:
- Basic and clinical studies to advance understanding of the biological mechanisms, both at the molecular, cellular and/or systems levels, that underlie AD/ADRD
- Basic and clinical studies to advance understanding of the similarities and differences in biological mechanisms and pathology between AD/ADRD and/or other neurodegenerative disorders and beyond
- Translational/preclinical studies to determine the scientific premise of potential therapeutic targets and investigational therapies of AD/ADRD
- Clinical studies to refine diagnoses of AD/ADRD, develop biomarkers, or advance understanding of the clinical sequelae of AD/ADRD
- Clinical research on health equities in AD/ADRD
Applicants for diversity-related career development programs will be expected to attach a Description of Candidate’s Contribution to Program Goals, explaining how the candidate’s participation would further the goals of the program to promote diversity in health-related research (see Notice of NIH’s Interest in Diversity NOT-OD-20-031).
The NINDS AD/ADRD Diversity K99/R00 award is intended for individuals who have no more than four years of postdoctoral research experience, and who require at least 12 months of mentored research training and career development (K99 phase) before transitioning to the R00 award phase of the program. This K99/R00 award can provide up to 5 years of support in two phases: up to 2 years for the K99 phase and up to 3 years for the R00 phase.
NIH Definition of a Postdoctoral Scholar(pdf, 395 KB)